The stock of Cerus Corporation (NASDAQ:CERS) hit a new 52-week low and has $4.13 target or 10.00% below today’s $4.59 share price. The 6 months bearish chart indicates high risk for the $454.31 million company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $4.13 price target is reached, the company will be worth $45.43M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 417,613 shares traded hands. Cerus Corporation (NASDAQ:CERS) has declined 21.59% since March 31, 2016 and is downtrending. It has underperformed by 24.11% the S&P500.
Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on November, 3. They expect $-0.16 EPS, up 5.88% or $0.01 from last year’s $-0.17 per share. After $-0.18 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts -11.11% EPS growth.
Cerus Corporation (NASDAQ:CERS) Ratings Coverage
Out of 2 analysts covering Cerus (NASDAQ:CERS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cerus has been the topic of 3 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Zacks downgraded the shares of CERS in a report on Tuesday, August 11 to “Buy” rating. BTIG Research maintained the shares of CERS in a report on Wednesday, August 19 with “Buy” rating. On Thursday, December 17 the stock rating was downgraded by Wedbush to “Neutral”.
According to Zacks Investment Research, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.”
Insitutional Activity: The institutional sentiment decreased to 1.69 in Q2 2016. Its down 0.06, from 1.75 in 2016Q1. The ratio is negative, as 10 funds sold all Cerus Corporation shares owned while 26 reduced positions. 8 funds bought stakes while 53 increased positions. They now own 66.39 million shares or 1.07% more from 65.69 million shares in 2016Q1.
Wasatch accumulated 105,000 shares or 0.01% of the stock. Parametric Associate Lc, a Washington-based fund reported 69,943 shares. Blackrock Grp Incorporated accumulated 0% or 36,246 shares. Birchview Capital L P accumulated 26,500 shares or 0.12% of the stock. Spot Trading Ltd Liability accumulated 22,039 shares or 0% of the stock. Hood River Cap Management Lc has 1.58% invested in the company for 1.89 million shares. Us Commercial Bank De has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Peak6 Limited Partnership reported 25,737 shares or 0% of all its holdings. Susquehanna Grp Inc Incorporated Limited Liability Partnership, a Pennsylvania-based fund reported 88,289 shares. Delta Lloyd Nv holds 500,000 shares or 0.1% of its portfolio. Steinberg Asset Mngmt holds 0.1% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 89,200 shares. Joel Isaacson And Co Ltd Co accumulated 15,000 shares or 0.02% of the stock. Granite Partners owns 235,176 shares or 0.12% of their US portfolio. Financial Architects Inc accumulated 0.03% or 15,500 shares. Cortina Asset Mngmt has 1.13 million shares for 0.32% of their US portfolio.
Insider Transactions: Since August 22, 2016, the stock had 0 insider buys, and 1 sale for $116,612 net activity. $116,612 worth of Cerus Corporation (NASDAQ:CERS) was sold by Green Kevin Dennis on Monday, August 22.
More news for Cerus Corporation (NASDAQ:CERS) were recently published by: Fool.com, which released: “Cerus Corporation is Surging Today. Here’s Why.” on June 20, 2016. Fool.com‘s article titled: “The Probable Reason Behind Cerus Corp’s 11.2% Drop in May” and published on June 09, 2016 is yet another important article.
CERS Company Profile
Cerus Corporation, incorporated on July 31, 1996, is a biomedical products company. The Firm is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Firm operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.